Danaher's growth has stabilized, with revenue expanding 5.5% in 2026Q2 after a cyclical trough, supported by resilient gross margins around 57.6% and strong cash conversion (OCF/NI of 1.76). The company is aggressively pursuing inorganic growth, allocating $9....
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth recovered to 5.5% in 2026Q2, with gross margin at 57.6% and operating margin at 18.0%, reflecting stabilization after a -19.8% contraction in 2024Q2.
Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology.
The company has shown strong bioprocessing recovery, contributing to a 14.14% stock price appreciation since previous coverage.
Management's conservative 2026 guidance sets a baseline that could be exceeded, with projected high-single-digit EPS growth and 3-6% core revenue growth.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 21, 2026 | $1.94+4.9% vs $1.85 | $6.3B+2.4% vs $6.1B |
Q2 2026 Apr 21, 2026 | $2.06+6.2% vs $1.94 | $6.0B-0.5% vs $6.0B |
Q1 2026 Jan 28, 2026 | $2.23+3.2% vs $2.16 | $6.8B+0.4% vs $6.8B |
Q4 2025 Oct 21, 2025 | $1.89+9.9% vs $1.72 | $6.1B+0.9% vs $6.0B |
WASHINGTON, Oct. 1, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms.
Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Danaher Corporation (NYSE: DHR). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Danaher stock on August 31st. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account. Representative Kevin Hern also recently made the following trade(s): Sold
Benchmark DHR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Danaher Corporation (DHR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $214.06 | $150.48B | 42.47 | 2.9% | 14.71% | 7.08% | 0.58% | |
| $654.80 | $243.34B | 36.91 | 3.91% | 15.06% | 13.33% | — | |
| $167.77 | $47.38B | 36.71 | 6.73% | 19.53% | 20.47% | — | |
| $425.21 | $31.8B | 39.52 | 6.99% | 3.58% | 1.88% | — | |
| $369.14 | $9.94B | 13.25 | 0.65% | 8.59% | 3.15% | — | |
| $63.24 | $9.63B | -421.60 | 2.08% | -2.03% | -2.87% | — |
Danaher Corporation (DHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Danaher Corporation (DHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jul 21, 2026·SEC
Jun 3, 2026·SEC
Get notified when DHR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Danaher Corporation (DHR) stock FAQ — growth, dividends, profitability & financials explained
Danaher Corporation (DHR) reported $25.11B in revenue for fiscal year 2025. This represents a 1286% increase from $1.81B in 1996.
Danaher Corporation (DHR) grew revenue by 2.9% over the past year. Growth has been modest.
Yes, Danaher Corporation (DHR) is profitable, generating $4.00B in net income for fiscal year 2025 (14.7% net margin).
Yes, Danaher Corporation (DHR) pays a dividend with a yield of 0.58%. This makes it attractive for income-focused investors.
Danaher Corporation (DHR) has a return on equity (ROE) of 7.1%. This is below average, suggesting room for improvement.
Danaher Corporation (DHR) generated $5.47B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
